The FDA grants Emergency Use Authorization for QIAGEN’s (NYSE:QGEN)
QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing
COVID-19 infection. The test can differentiate the SARS-CoV-2 viral
infection from 21 other serious respiratory infections in about an hour
from nasopharyngeal swabs.
Related ticker: Thermo Fisher Scientific (NYSE:TMO)
https://seekingalpha.com/news/3556638-fda-oks-emergency-use-of-qiagen-coronavirus-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.